Abstract
New family of tetrapodal compounds entitled 3-(bis((5-methyl-1-((2-isopentyl-2H-tetrazol-5-yl)methyl)-1H-pyrazol-3 yl)methyl)amino)propan-1-ol.(T1),2-(4-(bis((5-methyl-1-((2-propyl-2H-tetrazol-5-yl)methyl)-1H-pyrazol-3-yl)methyl)amino)phenyl)ethan-1-ol.(T2),N,N-bis((1-((2-isopentyl-2H-tetrazol-5-yl)methyl)-5-methyl-1H-pyrazol-3-yl)methyl)propan-1-amine.(T3).and.N,N-bis((1-((2-isopentyl-2H-tetrazol-5-yl)methyl)-5-methyl-1H-pyrazol-3-yl)methyl)propan-2 amine (T4) were synthesised as drug candidates to treat Type 2 diabetes. Their structures as the intermediates compounds were ensured by NMR and FTIR analysis as well as the spectrometric methods including high-resolution mass spectrometry and elemental analysis. The tetrapodal molecules were obtained in moderate yields in the range of 37–45 %. Their anti-diabetic activity was evaluated based on their α-amylase inhibition potency by determining their IC50 values. The obtained results showed that the tetrapodal compounds possess potent α−amylase inhibition activity 3 to 236 times higher than that of the acarbose, used as positive control. These findings were also supported by docking calculations.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
